Entrar/Registro  
INICIO ENGLISH
 
Cirujano General
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Cirujano General >Año 2015, No. 1-2


González-Izquierdo JJ, Hernández-Aguilar TJ, Palomares-Chacón UR, Castelltor HLF, Pérez NJV, Anaya-Prado R
Tratamiento actual de la enfermedad por reflujo gastroesofágico
Cir Gen 2015; 37 (1-2)

Idioma: Español
Referencias bibliográficas: 47
Paginas: 38-43
Archivo PDF: 190.25 Kb.


Texto completo




RESUMEN

La enfermedad por reflujo gastroesofágico se define como una falla de la barrera antirreflujo que determina un paso anormal de secreciones digestivas altas al esófago y produce síntomas con daño esofágico y extraesofágico. Los mecanismos fisiológicos que impiden el reflujo son el aclaramiento, el esfínter esofágico inferior y el vaciamiento gástrico adecuado. El fracaso en estos mecanismos de defensa permite el reflujo gastroesofágico. El tratamiento quirúrgico de la enfermedad por reflujo gastroesofágico ha estado en constante evolución durante los últimos 70 años. La funduplicatura de Nissen, la de Belsey y la gastropexia de Hill han sido estudiadas y modificadas con el paso del tiempo; se han realizado diferentes tipos de abordajes. Un tratamiento efectivo es reducir la secreción ácida del estómago, bien sea con antagonistas de los receptores H2, bien con inhibidores de la bomba de protones; la dosis dependerá de la severidad de cada paciente, ya que cuanto mayor sea la exposición esofágica al ácido, mayor será el grado de supresión que se requerirá para sanar. Actualmente existe mucho debate en cuanto a los beneficios del tratamiento médico frente al quirúrgico y el papel de la laparoscopia como cirugía de primer tiempo o como segundo abordaje. El objetivo de este artículo es determinar las opciones terapéuticas quirúrgicas y médicas que tenemos actualmente en nuestro medio.


Palabras clave: Enfermedad por reflujo gastroesofágico, funduplicatura, inhibidor de la bomba de protones.


REFERENCIAS

  1. Christian DJ, Buyske J. Current status of antireflux surgery. Surg Clin North Am. 2005; 85: 931-947.

  2. Kahrilas P. Gastroesophageal reflux disease. JAMA. 1996; 276: 983-988.

  3. Hirschowitz BI. Management of refractory and complicated reflux esophagitis. Yale J Biol Med. 1996; 69: 271-281.

  4. El-Serag H, Hill C, Jones R. Systematic review: The epidemiology of gastro-oesophageal reflux disease in primary care, using the UK general practice research database. Aliment Pharmacol Ther. 2009; 5: 470-480.

  5. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut. 2005; 54: 710-717.

  6. Bainbridge ET, Temple JG, Nicholas SP, et al. Symptomatic gastro-oesophageal reflux in pregnancy: a comparative study of white Europeans and Asians in Birmingham. Br J Clin Pract. 1983; 37: 53-57.

  7. Mittal R, Holloway R, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology. 1995; 109: 601-610.

  8. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest. 1980;65:256-67.

  9. Vakil N, van Zanten SV, Kahrilas PJ, et al., Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101: 1900-1920; quiz 1943.

  10. Kahrilas PJ. Anatomy and physiology of the gastroesophageal function. Gastroenterol Clin North Am. 1997; 26: 467-486.

  11. Richards WG, Sugarbaker DJ. Neuronal control of esophageal function. Chest Surg Clin N Am. 1995; 5: 157-171.

  12. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999; 45: 172-180.

  13. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006; 101: 1956-1963.

  14. Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: ‘on’ or ‘off’ proton pump inhibitor? Am J Gastroenterol. 2008; 103: 2446-2453.

  15. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med.1991; 151: 448-454.

  16. Bell N, Hunt R. Role of gastric acid suppression in the treatment of gastroesophageal reflux disease. Gut. 1992; 33: 118-124.

  17. Harvey RF, Gordon PC, Hadley N, et al. Effects of sleeping with the bedhead raised and of ranitidine in patients with severe peptic oesophagitis. Lancet. 1987; 2: 1200-1203.

  18. DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100: 190-200.

  19. Mathias SD, Colwell HH, Miller DP, et al. Health-related quality-of-life and quality-days incrementally gained in symptomatic none rosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci. 2001; 46: 2416-2423.

  20. Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am. 1990; 19: 683-712.

  21. Savarino V, Dulbecco P. Optimizing symptom relief and preventing complications in adults with gastro-oesophageal reflux disease. Digestion. 2004; 69: 9-16.

  22. Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011; 34: 618-627.

  23. Lind T, Havelund T, Carlsson R. Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997; 32: 974-979.

  24. Hatlebakk J, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux esophagitis: results of a Scandinavian multicentre trial. Scand J Gastroenterol. 1993; 28: 224-228.

  25. Feldman M, Harford W, Fisher R, et al. Treatment of reflux esophagitis resistant to H2 receptor antagonists with lansoprazolea new H+/K sup+-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol. 1993; 88: 1212-1217.

  26. Klinkenberg-Knol E, Festen H, Jansen J, et al. Long term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994; 121: 161-167.

  27. Richter J, Long J. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double blind study. Am J Gastroenterol.1995; 90: 423-430.

  28. Galmiche J, Brandsatter, Evreux M, et al. Combined therapy with cisapride and cimetidine in severe oesophagitis: a double blind controlled trial. Gut. 1988; 29: 675-681.

  29. Catarci M, Gentileschi P, Papi C, et al. Evidence-based appraisal of anti-reflux fundoplication. Ann Surg. 2004; 239: 325-337.

  30. Metz DC. Long-term outcome of laparoscopic Nissen and laparoscopic Toupet fundoplication for gastroesopahgeal reflux disease: a prospective, randomized trial. Surg Endosc. 2011; 24: 924-932.

  31. Nijjar RS, Watson D, Jamieson GG, et al. Five-year follow-up of a multicenter, double-blind randomized clinical trial of laparoscopic Nissen vs anterior 90 degrees partial fundoplication. Arch Surg. 2010; 145: 552-557.

  32. Markar SR, Karthikesalingam AP, Wagner OJ, et al. Systematic review and meta-analysis of laparoscopic Nissen fundoplication with or without division of the short gastric vessels. Br J Surg. 2011; 98: 1056-1062.

  33. Koch OO, Kaindlstorfer A, Antoniou SA, et al. Laparoscopic Nissen versus Toupet fundoplication: objective and subjective results of a prospective randomized trial. Surg Endosc. 2012; 26: 413-422.

  34. Oelschlager BK, Petersen RP, Brunt LM, et al. Laparoscopic paraesophageal hernia repair: Defining long-term clinical and anatomic outcomes. J Gastrointest Surg. 2012; 16: 453-459.

  35. Attwood SEA, Lundell L, Ell C, et al. Standardization of surgical technique in antireflux surgery: the LOTUS trial experience. World J Surg. 2008; 32: 995-958.

  36. Anvari M, Allen C, Marshall J, et al. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up. Surg Innov. 2006; 13: 238-249.

  37. Hunter JG, Smith CD, Branum GD, et al. Laparoscopic fundoplication failures: patterns of failure and response to fundoplication revision. Ann Surg. 1999; 230: 595-604.

  38. Willeman S, McCann S, Grant A, et al. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev. 2010; 17: CD003243.

  39. Attwood SE, Lundell L, Hatlebakk JG, et al. Medical or surgical management of GERD patients with Barrett’s esophagus: The LOTUS trial 3-year experience. J Gastrointest Surg. 2008; 12: 1646-1654.

  40. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastrooesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 2008; 57: 1207-1213.

  41. Cookson R, Flood C, Koo B, et al. Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton pump inhibitor maintenance for gastro-oesophageal reflux disease. Br J Surg. 2005; 92: 700-706.

  42. Decadt B, Lowndes R, Rhodes M. Prospective randomized trial of laparoscopic Nissen fundoplication (LNF) versus maintenance proton pump inhibition (PPI) in the treatment of gastro-oesophageal reflux disease (GORD): manometric findings. Gastroenterology. 1999; 116: A146.

  43. Grant A, Wileman S, Ramsay C, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease —a UK collaborative study. The REFLUX trial. Health Technol Assess. 2008; 12: 1-181, iii-iv.

  44. Grant AM, Wileman SM, Ramsay CL, et al. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008; 337: a2664.

  45. Metha S, Bennett J, Mahon D, et al. Prospective trial of laparoscopic Nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: Seven-year follow-up. J Gastrointest Surg. 2006; 10: 1312-1317.

  46. Anvari M, Allen C, Marshall J, et al. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastrooesophageal reflux disease (GERD): 3 year outcomes. Surg Endosc. 2011; 25: 2547-2554.

  47. Faria R, Bojke L, Epstein D, et al. Cost effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of GERD based on long-term follow-up of the REFLUX trial. Br J Surg. 2013; 100: 1205-1213.



>Revistas >Cirujano General >Año2015, No. 1-2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019